Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

NCT04032704 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT04032704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04032704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 9, 2019
Completion date
November 28, 2023
Enrollment
205 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, non-squamous, non-small cell lung cancer, squamous, prostate cancer, small cell lung cancer